Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | WRN | Q14191 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067032 | 1.00 | GSK3A (0.36) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| SCHEMBL10067027 | 0.92 | PTGS1 (0.39) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| Ether SCHEMBL515801 | 0.79 | GSK3A (0.33) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| SCHEMBL10018581 | 0.77 | MGLL (0.38) | ALDH1A1HPGDCYP1A2CYP2C19BLM | |
| SCHEMBL2226946 | 0.77 | PTGS1 (0.42) | ALDH1A1HPGDHSP90AA1HTTNPSR1 | |
| SCHEMBL513993 | 0.77 | PTGS1 (0.40) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| SCHEMBL513992 | 0.77 | PTGS1 (0.40) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| SCHEMBL15362286 | 0.75 | GSK3A (0.41) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| SCHEMBL16533055 | 0.75 | GSK3A (0.41) | GSK3AGSK3BALDH1A1HPGDCYP1A2 | |
| SCHEMBL15892740 | 0.74 | MGLL (0.35) | ALDH1A1HPGDHSP90AA1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534269-B1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GEN HOSPITAL CORP (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8361442-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-02 | — | — | US | disclosed |
| US-8030459-B2 | Oxime conjugates and methods for their formation and use | THE GENERAL HOSPITAL CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | ENERGY, UNITED STATES DEPARTMENT OF | 2006-03-16 | — | — | US | disclosed |
| EP-1534269-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004009082-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | THE GENERAL HOSPITAL CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058513-A1 | Oxime conjugates and methods for their formation and use | GNE, OGA, SORD | GSK3A 404/4885GSK3B 492/4885ALDH1A1 108/4885 |
| US-20120027680-A1 | OXIME CONJUGATES AND METHODS FOR THEIR FORMATION AND USE | GNE, SORD, OGA | GSK3A 396/4885GSK3B 489/4885ALDH1A1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.